In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting
Shule Wang, Ran Kong, Guangcai Zhong, Xinyu Yang, Xiangxiang Zhou · 2026
Read In vivo CAR-T therapy: latest updates from the 2025 ASH annual meeting by Shule Wang, Ran Kong, Guangcai Zhong, Xinyu Yang, Xiangxiang Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13198039.txt.
Description
Shule Wang and colleagues summarize in vivo CAR-T therapy updates from a 2025 meeting in a 2026 review. CAR-T therapy reprograms a patient's immune cells to attack blood cancers. Standard care builds those cells in a lab, a slow and costly path that also needs strong chemotherapy first.
In vivo therapy instead delivers the reprogramming code straight into the body, so T cells are edited in place. The review compares four delivery routes: viral carriers, RNA in fat particles, non-viral DNA, and gene-writing tools. Each route trades off on targeting, lasting effect, repeat dosing, and safety. Early clinical work is under way. The field could widen access if safety holds up.
Catalog record
| CREATOR | Shule Wang, Ran Kong, Guangcai Zhong, Xinyu Yang, Xiangxiang Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |